27 July 2016 - The TGA has approved three new indications for Abbvie's Humira (adalimumab).

The TGA approved Humira on 18 July 2016 for the treatment of:

• enthesitis-related arthritis in children, who have had an inadequate response to, or who are intolerant to, conventional therapy
• moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy
• severe chronic plaque psoriasis in children and adolescent patients from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapy

Read Humira Product Information